Noggin and sclerostin are bone morphogenetic protein (BMP) antagonists that modulate mitogenic activity through sequestering BMPs. Little is known of the interactions among this class of proteins. We show that recombinant sclerostin and noggin bound to each other with high affinity (K D ‫؍‬ 2.92 nM). This observation has been extended to naturally expressed noggin and sclerostin from the rat osteosarcoma cell line, ROS 17/ 2.8, supporting a role for the complex in natural systems. The noggin-sclerostin complex was competitive with BMP binding and mutually attenuated the activity of each BMP antagonist. Collectively, the data demonstrate a novel and exquisite paradigm for the regulation of BMP activity through direct neutralization of the BMP and activation by co-localized BMP antagonist expression. The pleiotrophic nature of noggin and sclerostin represents a novel mechanism for the fine-tuning of BMP activity in bone homeostasis.
Sclerostin, the protein product of the SOST gene, is absent in sclerosteosis, a skeletal disease characterized by bone overgrowth and strong dense bones (1, 2) . We have demonstrated that sclerostin, a bone morphogenetic protein (BMP) 1 antagonist highly expressed by osteocytes, is a key regulator of bone formation in vivo and in vitro (3) . A number of BMP antagonists have been described that historically were associated with important regulatory activity in developmental systems. Recent studies have expanded the roles of these proteins beyond the described embryonic roles. Noggin has been shown to be expressed in mineralizing tissue, and in in vivo experiments an essential role in joint formation was established (4 -9) . The overexpression of either sclerostin or noggin in bone cells leads to osteopenia in rodents, demonstrating the importance of BMP proteins in bone homeostasis and suggesting that sclerostin and noggin function as negative regulators of bone density (3, 4, 9) .
BMPs have been shown to induce the expression of BMP antagonists in mesenchymal (preosteoblastic) and osteoblastic cell lines (10, 11) . In vivo, the highest expression of sclerostin in adult human bone was seen in hypertrophic chondrocytes and osteocytes throughout the skeleton (3) . In comparison, in vivo, noggin expression was reported to be associated with chondrocytes (12) and osteoblasts of cranial sutures (7) . Given the close localization of these two BMP antagonist proteins and the similarity of their activities in vitro, we asked how these proteins might interact in regulating bone formation via limiting BMP activity. We report that these proteins coordinate their activity but do so through an unexpected pathway. Sclerostin and noggin bind to each other with high affinity and attenuate the BMP antagonist activity of each other. We propose that these BMP antagonists are pleiotrophic.
EXPERIMENTAL PROCEDURES
The Binding of Noggin and Sclerostin-Anti-FLAG M2-agarose beads (Sigma) were washed with IP buffer (20 mM Tris, pH 7.6, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1.4 mM ␤ME, 10% glycerol) before incubation in the presence or absence of 4 g of human sclerostin-FLAG (3). Unbound sclerostin-FLAG was removed by washing with IP buffer. The beads and tubes were blocked to prevent nonspecific binding by preincubation with 5% bovine serum albumin in phosphate-buffered saline and washed with IP buffer. Noggin-Fc (R&D Systems, Minneapolis, MN) was diluted into IP buffer (5 g/ml), centrifuged to remove aggregated protein, added to the beads (20 l packed) with or without sclerostin-FLAG, and incubated for 2 h at 4°C. The washed samples were analyzed on a 10 -20% gradient Tris-glycine SDS-PAGE gel (Novex, San Diego, CA), transferred to nitrocellulose, and the Western blots developed with a goat anti-noggin antibody (R&D Systems).
Biacore Analysis-Recombinant noggin-Fc was hydrated (100 g/ml) in phosphate-buffered saline (pH 7.3) with 1 mg/ml radioimmunoassay grade bovine serum albumin and 1 mg/ml carboxyl-methyl dextran. The running buffer for Biacore analysis was HBS-EP CMD (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.005% polysorbate 20, and 1 mg/ml carboxyl-methyl dextran). For kinetic analysis, Biacore CM5 sensor chips were coated with 200 response units of purified human sclerostin-FLAG using NHS/EDC chemistry, as recommended by the manufacturer (Biacore, Piscataway, NJ). Noggin-Fc was diluted in running buffer and injected over the sensor chip using a Biacore 3000. The data were processed using the Bia evaluation software by first correcting for background binding in a non-functionalized flow cell and analyzing the resulting binding curves for on/off rates.
Biacore Competition Assays-BMP-6 protein (20 g/ml in HBS-EP CMD) was injected over 200 response units of human sclerostin-FLAG on a CM5 chip followed by noggin (10 g/ml in HBS-EP CMD). The resulting curve was compared with the control, a BMP-6 injection followed by running buffer. Subtraction of the BMP6/running buffer curve from the BMP-6/noggin curves allowed the visualization of noggin binding after BMP-6. This binding was then compared with noggin binding after running buffer.
ELISA Competition Assays-ELISA binding assays for sclerostin binding to noggin and BMP-6 protein were performed as described previously (3) . Noggin (40 nM) or BMP-6 (40 nM) was added at a constant concentration followed by titration with anti-sclerostin antibodies (3) . The binding of BMP-6 or noggin-Fc to sclerostin was detected with appropriate primary (anti-human BMP-6 for BMP-6, anti-human Fc for noggin) and secondary reagents.
SMAD Assays-To assay for SMAD phosphorylation, confluent 6-well plates of mouse C3H10T1/2 cells were serum-depleted overnight in medium containing 1% fetal calf serum. BMP-6 was preincubated in medium with or without 5 g/ml noggin-Fc and varying amounts of human sclerostin-FLAG or bone morphogenetic receptor IA (BMPRIAFc) for 1 h at room temperature prior to addition to cells. Detection was performed as previously described (3).
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‡ To whom correspondence should be addressed: 2409 10th Ave. W., Seattle, WA 98119. Tel.: 206-719-4450; E-mail: latham@alderbio.com. 1 The abbreviations used are: BMP, bone morphogenetic protein; BMPRIA, bone morphogenetic receptor IA; ELISA, enzyme-linked immunosorbent assay; ROS, rat osteosarcoma; IP, immunoprecipitation. Reverse Transcriptase-PCR-ROS 17/2.8 cells were maintained in ␣-minimum essential medium, with glutamine ϩ 10% heat-inactivated fetal bovine serum (Hyclone, Logan, UT). RNA was prepared using Strataprep Absolutely RNA miniprep kits (Stratagene, San Diego, CA). cDNA synthesis was performed using 1 g of total RNA, oligo(dT) primers, and the Superscript first strand cDNA synthesis system according to the manufacturer's directions (Invitrogen). PCR was performed using Platinum TaqDNA polymerase (Invitrogen) and the following PCR primers to detect the expressions of rat SOST, noggin, and the housekeeping gene Defender Against Death (DAD). Primer sets crossed intron/exon boundaries when possible to eliminate amplification of genomic DNA or the generation of larger size amplicons. All PCR products were verified by sequencing.
The primers were SOST (product size 369 nucleotides): sense, 5Ј-C-CTTGCCTTGCCTGCCTGCTTGTA-3Ј, antisense, 5Ј-GTCCGTTCGGG-CGCCACCACTTC-3Ј; Noggin (263 nucleotides): sense, 5Ј-CCATGCCG-AGCGAGATCA-3Ј, antisense, 5Ј-CACGGTGAGGTGCACAGACTT-3Ј; and DAD (200 nucleotides): sense, 5Ј-TCCTCTTTGCCAGCACGATCC-TG-3Ј, antisense, 5Ј-AGAGCGAAGGGAGTTCTCTGGACGTGCC-ACC-3Ј.
Isolation of Sclerostin-Noggin Complexes from ROS Cell-conditioned Medium-Conditioned medium was harvested from ROS cells grown in 10-chamber cell factories (Nunc, Naperville, IL). The mouse monoclonal H88 anti-sclerostin antibody (2 mg) or a normal mouse IgG (Sigma) was linked to a 2-ml carbo-link affinity resin column (Pierce). 500 ml of conditioned or control medium was used for immunoprecipitation of sclerostin. Columns were washed with 50 ml of phosphate-buffered saline and 30 ml of IP buffer followed by elution with 10 mM glycine buffer, pH 2.5. Eluted proteins and similar fractions from control columns were separated on SDS-PAGE and developed by Western blot using BMP-2, BMP-5, and noggin antibodies (R&D Systems).
For noggin immunoprecipitation, conditioned medium or control medium were incubated with the goat anti-noggin polyclonal antibody (100 g) or normal goat IgG (100 g) (Vector Labs, Burlingame, CA) linked to amino-link resin (Pierce-Endogen). Immunoprecipitates were washed with phosphate-buffered saline and IP buffer as described above, and samples were analyzed by SDS-PAGE. Western blots were developed with a rabbit anti-rat sclerostin monoclonal antibody.
RESULTS
Noggin and Sclerostin Binding-To test for interaction between sclerostin and noggin, recombinant noggin-Fc fusion protein was incubated with FLAG resin in the presence and absence of baculovirus-produced sclerostin-FLAG (3). Specific binding was detected only in the presence of the sclerostin-FLAG protein (Fig. 1A) . Biacore analysis demonstrated high affinity binding (2.92 nM K D ) of noggin to sclerostin immobilized on a CM5 chip (Fig. 1B) . The observed affinity was on par with that of sclerostin for the BMP proteins (3). The noggin-sclerostin interaction was unexpected because there have been no prior reports of BMP antagonist-BMP antagonist interactions.
Noggin and Sclerostin Interaction Is Competitive and Exclusive of BMP Binding-Using Biacore methodology, we interrogated the underlying properties of the noggin-sclerostin complex. We addressed the fundamental BMP-BMP antagonist interaction by specifically asking whether the binding sites overlapped. Recombinant human sclerostin was immobilized on a CM-5 chip. To test for competition, we compared the binding of noggin to sclerostin after an injection of running buffer or after an injection of BMP-6 protein to saturate the BMP-binding pocket. Analyses of the binding curves allowed direct comparison of the noggin-binding component under these conditions. Limited binding of noggin to sclerostin was observed when the sclerostin-CM5 chip was presaturated with BMP-6 ( Fig. 2A) . These data show that the sclerostin-BMP complex did not bind to noggin and conversely that the sclerostin-noggin complex did not bind to BMP proteins, indicating that these interactions are competitive and exclusive of each other.
An Anti-sclerostin Monoclonal That Blocks Sclerostin Binding to BMPs Also Blocks the Binding of Sclerostin to Noggin-
ELISA-based assays for noggin and BMP-6 binding to sclerostin were developed (3) to further evaluate the sclerostin-noggin interaction. In these assays, sclerostin was coated onto polysorp plates, noggin or BMP-6 was added at a constant concentration, and anti-sclerostin antibodies were titrated in. The BMP-6 or noggin binding to sclerostin was then detected. The CCH 501 anti-sclerostin antibody competitively inhibited the binding of both BMP-6 and noggin proteins to sclerostin in a dose-dependent manner (Fig. 2, B and C) . These findings suggest that BMP-6 and noggin bound to similar, or at least competitive, sites on the sclerostin protein. A control monoclonal antibody raised against the sclerostin protein does not compete with either binding event (CCH 502).
Sclerostin and Noggin Block the BMP Antagonist Activity of Each Other-BMP-6 induced the phosphorylation of SMADs 1, 5, and 8 in mouse C3H10T1/2 cells (Fig. 3A) . The addition of noggin or sclerostin inhibited this BMP activity (Fig. 3A) (3) . To determine whether sclerostin and noggin could block the BMP antagonist activity of each other, the concentration of noggin was fixed at 5 g/ml and sclerostin was titrated from 40 g/ml down to a stoichiometric ratio of the two proteins (2.5 g/ml sclerostin, 5 g/ml noggin-Fc). At the highest concentration of sclerostin, SMAD phosphorylation was suppressed, suggesting that the BMP was in an antagonistic complex with sclerostin. When the levels of sclerostin and noggin were equivalent, the BMP-6-induced SMAD phosphorylation was recovered. The Western blots were subjected to image analysis to quantitate B, specific precipitation of BMP-2 in a complex with sclerostin from ROS cell-conditioned medium using the H88 anti-sclerostin antibody. No BMP-2 is seen either with a control IP of non-conditioned medium or with a normal mouse IgG antibody with either conditioned or non-conditioned medium. Western control for BMP-2 using recombinant BMP-2 at 50 and 20 ng/lane as labeled. C, specific precipitation of BMP-5 in a complex with sclerostin from ROS cell-conditioned medium using the H88 anti-sclerostin antibody. No BMP-5 product is seen either with a control IP of non-conditioned medium or with a normal mouse IgG antibody with either conditioned or non-conditioned medium. Anti-BMP-5 Western blot, arrow points to specific IP product. Western control for BMP-5 uses recombinant BMP-5 at 50 and 20 ng/lane as labeled and is overloaded. D, specific precipitation of noggin in a complex with sclerostin from ROS cell-conditioned medium using the H88 antibody. No noggin product is seen either with a control IP of non-conditioned medium or with a normal mouse IgG antibody with either conditioned or non-conditioned medium. Anti-noggin Western blot, arrow points to specific IP product. Western control is noggin-Fc (ϳ55 K D ) at 50 ng/lane. E, specific precipitation of sclerostin in a complex with noggin from ROS cell-conditioned medium using an anti-noggin antibody. No sclerostin product is seen either with a control IP of non-conditioned medium or with a normal mouse IgG antibody with either conditioned or non-conditioned medium. Anti-sclerostin Western blot, arrow points to specific IP product. Recombinant sclerostin is the Western control at 5 ng/lane. the amount of SMAD phosphorylation. Under these conditions, the sclerostin and noggin were in complex with each other and unable to bind and antagonize BMP activity (Fig. 3, A and C) . Similar experiments were conducted with the soluble BM-PRIA-Fc added to a constant concentration of noggin (Fig. 3, B  and D) . In contrast to the experiment with sclerostin, SMAD phosphorylation was decreased throughout the BMPRIA-Fc dose curve (Fig. 3, B and D) . These data show that the BMP antagonists, noggin and sclerostin, were able to attenuate the activity of each other by forming a "dead end" complex that could not bind BMP proteins, allowing BMP signaling to proceed.
Isolation of Sclerostin-Noggin Complexes from ROS Cell-conditioned Medium-We next addressed whether our biochemical observations translated into complexes obtained from a more native setting, i.e. where both BMP antagonist proteins are naturally produced. The rat osteosarcoma cell line, ROS 17/2.8, was found to naturally express sclerostin and noggin (Fig. 4A) . A mouse monoclonal anti-sclerostin antibody (H88) or a control mouse IgG was covalently immobilized to a matrix support. ROS cell-conditioned medium or control medium was passed over the matrix. The bound proteins were washed extensively and eluted with low pH buffer. Fractions were interrogated by Western blot for the presence of sclerostin, BMP proteins, and noggin. Sclerostin was clearly seen in complex with BMP-2, BMP-5, and noggin (Fig. 4, B-D) . These proteins were not seen in complex with the control mouse IgG antibody, highlighting the specificity of the immunoprecipitations.
To further examine the noggin-sclerostin interaction, a goat anti-noggin polyclonal antibody or control goat IgG was covalently immobilized to a matrix support. Conditioned medium from ROS cells or control medium was passed over the matrix, the matrix was washed extensively, and the eluted proteins were examined for the presence of sclerostin by Western blot analysis. Specific co-immunoprecipitation of sclerostin was seen (Fig. 4E) . Collectively, these co-immunoprecipitation data establish that the sclerostin-noggin complex was formed in a setting where both proteins were naturally expressed.
DISCUSSION
BMPs have roles in morphogenesis during development and in regulatory pathways such as those affecting bone density. BMP activity is highly regulated by limited expression and by the well described coordinated expression of BMP antagonists such as noggin. In development, often multiple antagonists, BMPs, and other morphogenic proteins are expressed in areas where growth-related decisions are needed (5).
Noggin has described roles in morphogenesis, including the control of dorsal ventral patterning, chondrogenesis, formation and maintenance of the apical epidermal ridge, digit formation, and control of eyelid opening, along with feather eruption (7, (13) (14) (15) (16) (17) (18) . The role of sclerostin in specific developmental stages is much less studied; however, we see the expression of SOST in the apical epidermal ridge. 2 Furthermore, sclerosteosis patients who have no detectable levels of sclerostin protein can exhibit fused digits in the hands, suggesting that SOST expressed in the apical epidermal ridge may affect digit formation (19) . Mice overexpressing human sclerostin from its own promoter also have limb defects, including missing and fused digits. 3 The similarity between the loss-of-function sclerostin mutations seen in the sclerosteosis patients and the phenotype in SOST transgenic mice points toward a mechanism of action where the lack of expression and the high expression levels of the sclerostin protein may activate the same pathways. The interaction between sclerostin and noggin suggests a new mechanism for fine-tuning the activity of BMPs at the apical epidermal ridge. The tight coordination and ultimate balance in expression of these two important regulatory proteins have the potential to influence the skeletal observations. BMP treatment of osteoblastic cells induces the expression of multiple BMP antagonists, including noggin, gremlin, and sclerostin (10, 11) . This temporal co-regulation suggests that the BMP antagonists may work together to modulate BMP activity in osteoblasts. In this study, we have shown mechanistically that the function of two of these BMP antagonists is not redundant. Instead, noggin and sclerostin interact and unexpectedly limit the activity of each other. This interaction is competitive and exclusive of their binding to BMP proteins. When noggin and sclerostin are complexed with each other, BMPs are available to bind to their receptors and induce downstream signaling as would have been the case when the BMPs are expressed in the absence of antagonists (Fig. 5) . We postulate that the balance of the expression of noggin, sclerostin, and BMP determines the activation state of these key pathways. Our data highlight that, mechanistically, noggin and sclerostin are pleiotrophic. They may affect BMP signaling pathways negatively as BMP antagonists, but when their expression overlaps, they can form a complex that allows BMP signaling to proceed. These observations expand the complexity used to control BMP-driven processes and highlight a new paradigm for influencing regulatory networks employing soluble antagonists.
